Predictive value of the efficacy of glaucoma medications in regulatory trials: Phase I-III to post-marketing studies

Eye

Volumn 22, Issue 8, 2008, Pages 985-988

  Stewart, W C ^a,b   Jenkins, J N ^a,b  

^a University of South Carolina   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; APRACLONIDINE; BETAXOLOL; BIMATOPROST; BRIMONIDINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; TIMOLOL; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

CLINICAL TRIAL; DRUG EFFICACY; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MEDICAL LITERATURE; MEDLINE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; POSTMARKETING SURVEILLANCE; PREDICTION; REVIEW; TREATMENT OUTCOME;

EID: 50449109326     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702913     Document Type: Review

References (65)

1. Nagasubramanian S, Hitchings RA, Demailly P, Chuniaud M, Pannarale MR, Pecori-Giraldi J et al. Comparision of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study. Ophthalmology 1993; 100(9): 1318-1323.
2. Abrams DA, Robin AL, Pollack IP, deFaller JM, DeSantis L. The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers. Arch Ophthalmol 1987; 105(9): 1205-1207.
3. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 1995; 113(8): 1009-1016.
4. Berry Jr DP, Van Buskirk EM, Shields MB. Betaxolol and timolol. A comparison of efficacy and side effects. Arch Ophthalmol 1984; 102(1): 42-45.
5. Weinreb RN, Caldwell DR, Goode SM, Horwitz BL, Laibovitz R, Shrader CE et al. A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution. Am J Ophthalmol 1990; 110(2): 189-192.
6. Feghali JG, Kaufman PL. Decreased intraocular pressure in the hypertensive human eye with betaxolol, a beta 1-adrenergic antagonist. Am J Ophthalmol 1985; 100(6): 777-782.
7. Caldwell DR, Salisbury CR, Guzek JP. Effects of topical betaxolol in ocular hypertensive patients. Arch Ophthalmol 1984; 102(4): 539-540.
8. Feghali JG, Kaufman PL, Radius RL, Mandell AI. A comparison of betaxolol and timolol in open angle glaucoma and ocular hypertension. Acta Ophthalmol (Copenh) 1988; 66(2): 180-186.
9. DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: A 30-day comparison with latanoprost. Surv Ophthalmol 2001; 45(Suppl 4): S353-S360.
10. Sherwood M, Brandt J, Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001; 45(Suppl 4): S361-S368.
11. Cohen JS, Gross RL, Cheetham JK, VanDenburgh AM, Bernstein P, Whitcup SM. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004; 49(Suppl 1): S45-S52.
12. Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM, Bimatoprost Circadian IOP Study Group. 24-H IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: A 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004; 49(Suppl 1): S26-S35.
13. Laibovitz RA, VanDenburgh AM, Felix C, David R, Batoosingh A, Rosenthal A et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: Dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol 2001; 119 (7): 994-1000.
14. Brubaker RF, Schoff EO, Nau CB, Carpenter SP, Chen K, Vandenburgh AM. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 2001; 131(1): 19-24.
15. Stewart WC, Stewart JA, Day D, Sharpe ED. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand 2003; 81 (3): 242-246.
16. Liu CJ, Ko YC, Cheng CY, Chiu AW, Chou JC, HsuWM et al. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients. Ophthalmology 2002; 109(12): 2241-2247.
17. Kampik A, Arias-Puente A, O'Brart DP, Vuori ML, European Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: A randomized observer-masked multicenter study. J Glaucoma 2002; 11(2): 90-96.
18. Konstas AG, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos NT. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am J Ophthalmol 2001; 131(6): 729-733.
19. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996; 41 (Suppl 1): S27-S37.
20. LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology 1998; 105(10): 1960-1967.
21. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999; 127(1): 20-26.
22. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997; 115(7): 847-852.
23. Derick RJ, Robin AL, Walters TR, Barnebey HS, Choplin N, Schuman J et al. Brimonidine tartrate: A one-month dose response study. Ophthalmology 1997; 104(1): 131-136.
24. Shin DH, Feldman RM, Sheu WP, Fixed Combination Latanoprost/Timolol Study Group. Efficacy and safety of the fixed combinations latanoprost/ timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 2004; 111(2): 276-282.
25. Konstas AG, Papapanos P, Tersis I, Houliara D, Stewart WC. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology 2003; 110(7): 1357-1360.
26. Konstas AG, Papapanos P, Tersis I, Houliara D, Stewart WC. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology 2003; 110(7): 1357-1360.
27. Strohmaier K, Snyder E, DuBiner H, Adamsons I. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology 1998; 105(10): 1936-1944.
28. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology 1998; 105(10): 1952-1959.
29. O'Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: A 3 month, randomised study. Ireland Latanoprost Study Group. Br J Ophthalmol 2000; 84 (6): 579-582.
30. Lippa EA, Carlson LE, Ehinger B, Eriksson LO, Finnstrom K, Holmin C et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992; 110(4): 495-499.
31. Heijl A, Strahlman E, Sverrisson T, Brinchman-Hansen O, Puustjarvi T, Tipping R. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Ophthalmology 1997; 104(1): 137-142.
32. Kitazawa Y, Azuma I, Iwata K, Tsukahara S, Shiose Y, Araie M et al. Dorzolamide, a topical carbonic anhydrase inhibitor: A two-week dose-response study in patients with glaucoma or ocular hypertension. J Glaucoma 1994; 3: 275-279.
33. Higginbotham EJ, Feldman R, Stiles M, Dubiner H, Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: One-year randomized trial. Arch Ophthalmol 2002; 120(7): 915-922.
34. Larsson LI. Effect on intraocular pressure during 24 h after repeated administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. J Glaucoma 2001; 10(2): 109-114.
35. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996; 103(1): 126-137.
36. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996; 103(1): 138-147.
37. Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol 2002; 47(Suppl 1): S77-S89.
38. Sponsel WE, Mensah J, Kiel JW, Remky A, Trigo Y, Baca W et al. Effects of latanoprost and timolol-XE on hydrodynamics in the normal eye. Am J Ophthalmol 2000; 130(2): 151-159.
39. Sponsel WE, Paris G, Trigo Y, Pena M. Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma. Am J Ophthalmol 2002; 134(4): 552-559.
40. Tsukamoto H, Mishima HK, Kitazawa Y, Araie M, Abe H, Negi A, Glaucoma Study Group. A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open-angle glaucoma and ocular hypertension. J Glaucoma 2002; 11(6): 497-501.
41. Kobayashi H, Kobayashi K, Okinami S. A comparison of intraocular pressure-lowering effect of prostaglandin F2 - alpha analogues, latanoprost, and unoprostone isopropyl. J Glaucoma 2001; 10 (6): 487-492.
42. Aung T, Chew PT, Yip CC, Chan YH, See JL, Khng CG et al. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 2001; 131(5): 636-642.
43. Saito M, Takano R, Shirato S. Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma. Am J Ophthalmol 2001; 132(4): 485-489.
44. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132(4): 472-484.
45. Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology 1993; 100(9): 1305-1311.
46. Alm A, Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol 1991; 109(11): 1564-1568.
47. Villumsen J, Alm A. PhXA34a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol 1992; 76(4): 214-217.
48. Alm A, Villumsen J, Tornquist P, Mandahl A, Airaksinen J, Tuulonen A et al. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology 1993; 100(9): 1312-1316 discussion 1316-1317.
49. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995; 102(12): 1743-1752.
50. Racz P, Ruzsonyi MR, Nagy ZT, Bito LZ. Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study. Arch Ophthalmol 1993; 111(5): 657-661.
51. Larsson LI, Mishima HK, Takamatsu M, Orzalesi N, Rossetti L. The effect of latanoprost on circadian intraocular pressure. Surv Ophthalmol 2002; 47(Suppl 1): S90-S96.
52. Camras CB, Wax MB, Ritch R, Weinreb R, Robin AL, Higginbotham EJ et al. Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group. Am J Ophthalmol 1998; 126(3): 390-399.
53. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 1998; 105 (1): 82-87.
54. Rulo AH, Greve EL, Geijssen HC, Hoyng PF. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology 1996; 103(8): 1276-1282.
55. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 1996; 114 (8): 929-932.
56. Stewart WC, Leland TM, Cate EA, Stewart JA. Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure. J Glaucoma 1998; 7(6): 402-407.
57. Schenker HI, Silver LH. Long-term intraocular pressure-lowering efficacy and safety of timolol maleate gel-forming solution 0.5% compared with Timoptic XE 0.5% in a 12-month study. Am J Ophthalmol 2000; 130 (2): 145-150.
58. Stewart RH, Kimbrough RL, Ward RL. Betaxolol vs timolol. A six-month double-blind comparison. Arch Ophthalmol 1986; 104(1): 46-48.
59. Zimmerman TJ, Kass MA, Yablonski ME, Becker B. Timolol maleate: Efficacy and safety. Arch Ophthalmol 1979; 97(4): 656-658.
60. Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 1977; 95(4): 601-604.
61. Katz IM, Hubbard WA, Getson AJ, Gould AL. Intraocular pressure decrease in normal volunteers following timolol ophthalmic solution. Invest Ophthalmol 1976; 15(6): 489-492.
62. LeBlanc RP, Saheb NE, Krip G. Timolol: Long-term Canadian multicentre study. Can J Ophthalmol 1985; 20(4): 128-130.
63. Stewart WC, Stewart JA, Holmes KT, Leech JN. Differences in ocular surface irritation between timolol hemihydrate and timolol maleate. Am J Ophthalmol 2000; 130(6): 712-716.
64. Sakurai M, Araie M, Oshika T, Mori M, Masuda K, Ueno R et al. Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol 1991; 35(2): 156-165 erratum in Jpn J Ophthalmol 1992;36(4):491.
65. Azuma I, Masuda K, Kitazawa Y, Takase M, Yamamura H. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol 1993; 37(4): 514-525.